Intravenous or oral iron for treating iron deficiency anaemia during pregnancy: systematic review and meta‐analysis

Alaa Qassim, Rosalie M Grivell, Amanda Henry, Giselle Kidson‐Gerber, Antonia Shand and Luke E Grzeskowiak
Med J Aust 2019; 211 (8): . || doi: 10.5694/mja2.50308
Published online: 21 October 2019


Objectives: To compare the effects on perinatal maternal and neonatal outcomes of intravenous and oral iron therapy as first‐line treatment of iron deficiency anaemia (IDA) in pregnant women.

Study design: A meta‐analysis, applying fixed and random effects models, of randomised controlled trials (RCTs) that compared the effects of intravenous and oral iron therapy for pregnant women with IDA.

Data sources: MEDLINE, EMBASE, Scopus, Cochrane Register of Controlled Trials, Web of Science; bibliographies of identified articles.

Data synthesis: Fifteen eligible studies with a total of 1938 participants were identified. Each was at high risk of bias in at least one domain; ten were undertaken in low or middle income countries. Evidence (from nine RCTs) that intravenous iron was superior to oral iron in reducing the need for blood transfusion at delivery was low quality (Peto odds ratio, 0.19 [95% CI, 0.05–0.78]; number needed to treat, 95 [95% CI, 81–348]). Evidence that intravenous iron was superior to oral iron in increasing neonatal birthweight (eight RCTs: mean difference, 58 g; 95% CI, 4–112 g) or reducing the rate of breastfeeding cessation within 24 months of delivery (one RCT: hazard ratio, 0.70; 95% CI, 0.50–0.99) was of low or very low quality. While intravenous iron treatment was superior to oral iron for improving maternal haematological parameters at delivery, their effects on neonatal haematological parameters were similar.

Conclusions: There is no strong evidence that first‐line therapy with intravenous iron is superior to oral administration for treating IDA in pregnant women. The few identified differences in outcomes were small in magnitude and from studies at high risk of bias.

Registration: International Prospective Register of Systematic Reviews (PROSPERO), CRD42019120652.

  • 1 University of South Australia, Adelaide, SA
  • 2 SA Pharmacy, SA Health, Adelaide, SA
  • 3 Flinders Medical Centre, Adelaide, SA
  • 4 Flinders University, Adelaide, SA
  • 5 St George Hospital, Sydney, NSW
  • 6 The George Institute for Global Health, Sydney, NSW
  • 7 University of New South Wales, Sydney, NSW
  • 8 Prince of Wales Hospital, Sydney, NSW
  • 9 Royal Hospital for Women, Sydney, NSW
  • 10 University of Sydney, Sydney, NSW
  • 11 The Robinson Research Institute, University of Adelaide, Adelaide, SA
  • 12 South Australian Health and Medical Research Institute, Adelaide, SA


Luke Grzeskowiak, Rosalie Grivell and Amanda Henry receive salary support from National Health and Medical Research Council Early Career Fellowships (APP1070421, APP1073514, APP1141570). Luke Grzeskowiak also receives salary support from a Robinson Research Institute Career Development Fellowship and a Lloyd Cox Research Fellowship from the University of Adelaide.

Competing interests:

No relevant disclosures.

  • 1. Stevens GA, Finucane MM, De‐Regil LM, et al; Nutrition Impact Model Study Group (Anaemia). Global, regional, and national trends in haemoglobin concentration and prevalence of total and severe anaemia in children and pregnant and non‐pregnant women for 1995–2011: a systematic analysis of population‐representative data. Lancet Glob Health 2013; 1: e16–e25.
  • 2. Haider BA, Olofin I, Wang M, et al. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta‐analysis. BMJ 2013; 346: f3443.
  • 3. Steer P, Alam MA, Wadsworth J, Welch A. Relation between maternal haemoglobin concentration and birth weight in different ethnic groups. BMJ 1995; 310: 489–491.
  • 4. Chang S, Zeng L, Brouwer ID, et al. Effect of iron deficiency anemia in pregnancy on child mental development in rural China. Pediatrics 2013; 131: e755–e763.
  • 5. Berglund SK, Torres‐Espínola FJ, García‐Valdés L, et al. The impacts of maternal iron deficiency and being overweight during pregnancy on neurodevelopment of the offspring. Br J Nutr 2017; 118: 533–540.
  • 6. Reveiz L, Gyte G, Cuervo LG. Casasbuenas A. Treatments for iron‐deficiency anaemia in pregnancy. Cochrane Database Syst Rev 2011; CD003094.
  • 7. Muñoz M, Peña‐Rosas J, Robinson S, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post‐partum period: NATA consensus statement. Transfus Med 2018; 28: 22–39.
  • 8. Shi Q, Leng W, Wazir R, et al. Intravenous iron sucrose versus oral iron in the treatment of pregnancy with iron deficiency anaemia: a systematic review. Gynecol Obstet Invest 2015; 80: 170–178.
  • 9. Seeho SK, Morris JM. Intravenous iron use in pregnancy: ironing out the issues and evidence. Aust N Z J Obstet Gynaecol 2018; 58: 145–147.
  • 10. Lewkowitz AK, Gupta A, Simon L, et al. Intravenous compared with oral iron for the treatment of iron‐deficiency anemia in pregnancy: a systematic review and meta‐analysis. J Perinatol 2019; 39: 519–532.
  • 11. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
  • 12. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924–926.
  • 13. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. Oxford: The Cochrane Collaboration, 2011. (viewed Mar 2019).
  • 14. Khalafallah A, Dennis A, Bates J, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010; 268: 286–295.
  • 15. Froessler B, Cocchiaro C, Saadat‐Gilani K, et al. Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. J Matern Fetal Neonatal Med 2013; 26: 654–659.
  • 16. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
  • 17. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14: 135.
  • 18. Efthimiou O. Practical guide to the meta‐analysis of rare events. Evid Based Ment Health 2018; 21: 72–76.
  • 19. Singh K, Fong Y, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol 1998; 60: 119–124.
  • 20. Bayoumeu F, Subiran‐Buisset C, Baka NE, et al. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol 2002; 186: 518–522.
  • 21. Al RA, Unlubilgin E, Kandemir O, et al. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106: 1335–1340.
  • 22. Khalafallah AA, Dennis AE, Ogden K, et al. Three‐year follow‐up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open 2012; 2: e000998.
  • 23. Aggarwal RS, Mishra V, Panchal NA, et al. Evaluation of iron sucrose and oral iron in management of iron deficiency anaemia in pregnancy. National Journal of Community Medicine 2012; 3: 55–60.
  • 24. Neeru S, Nair NS, Rai L. Iron sucrose versus oral iron therapy in pregnancy anemia. Indian J Community Med 2012; 37: 214–218.
  • 25. Dubey S, Suri V, Aggarawal N, Das R. Is it safe to use intravenous iron sucrose during pregnancy? A randomized controlled trial. International Journal of Reproduction, Contraception, Obstetrics and Gynecology 2013; 2: 544–549.
  • 26. Kochhar PK, Kaundal A, Ghosh P. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. J Obstet Gynaecol Res 2013; 39: 504–510.
  • 27. Gupta A, Manaktala U, Rathore AM. A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy. Indian J Hematol Blood Transfus 2014; 30: 120–125.
  • 28. Abhilashini G, Sagili H, Reddi R. Intravenous iron sucrose and oral iron for the treatment of iron deficiency anaemia in pregnancy. J Clin Diagn Res 2014; 8: 4–7.
  • 29. Rudra S, Chandna A, Nath J. Comparison of intravenous iron sucrose with oral iron in pregnant women with iron deficiency anaemia. Int J Reprod Contracept Obstet Gynecol 2016; 5: 747–751.
  • 30. Breymann C, Milman N, Mezzacasa A, et al. FER‐ASAP investigators. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open‐label, randomized controlled trial (FER‐ASAP). J Perinat Med 2017; 45: 443–453.
  • 31. Ruangvutilert P, Chanprapaph P, Chuenwattana P, et al. Low‐dose weekly intravenous iron sucrose versus daily oral iron for iron deficiency anemia in late pregnancy: a randomized controlled trial. Journal of the Medical Association of Thailand 2017; 100: 496–503.
  • 32. Sarmishta M. A comparative study of oral iron therapy versus intravenous iron therapy in moderately pregnant anaemic women (7–10g/dl). Research Journal of Pharmaceutical, Biological and Chemical Sciences 2017; 8: 327–333.
  • 33. IRONMAN Investigators; Litton E, Baker S, Erber WN, et al; Australian and New Zealand Intensive Care Society Clinical Trials Group. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial. Intensive Care Med 2016; 42: 1715–1722.
  • 34. Low MSY, Grigoriadis G. Iron deficiency and new insights into therapy. Med J Aust 2017; 207: 81–87.
  • 35. Qassim A, Gergis RG, Jeffries B, et al. Use of intravenous iron polymaltose in the management of iron deficiency in pregnancy: a retrospective cohort study. Aust N Z J Obstet Gynaecol 2018; 58: 163–169.
  • 36. Qassim A, Mol BW, Grivell RM, Grzeskowiak LE. Safety and efficacy of intravenous iron polymaltose, iron sucrose and ferric carboxymaltose in pregnancy: a systematic review. Aust N Z J Obstet Gynaecol 2018; 58: 22–39.
  • 37. Grzeskowiak LE, Qassim A, Jeffries B, Grivell RM. Approaches for optimising intravenous iron dosing in pregnancy: a retrospective cohort study. Intern Med J 2017; 47: 747–753.
  • 38. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta‐analysis of randomised clinical trials. BMJ 2013; 347: f4822.
  • 39. Boughton S, Chen L, Kidson‐Gerber G, et al. Intravenous iron sucrose and ferric carboxymaltose in pregnant patients: an observational study of maternal efficacy and tolerance. Journal of Pharmacy Practice and Research 2017; 47: 419–425.
  • 40. Isbister JP, Shander A, Spahn DR, et al. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev 2011; 25: 89–101.
  • 41. Anker SD, Comin Colet J, Filippatos G, et al; FAIR‐HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436–2448.
  • 42. Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015; 314: 2062–2068.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.